Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0000921895-26-000850 0002042077 XXXXXXXX LIVE 1 Common Stock, $0.01 par value 04/06/2026 true 0001227636 64131A105 Neuronetics, Inc. 3222 PHOENIXVILLE PIKE MALVERN PA 19355 Jorey Chernett (248) 469-8811 6222 Indianwood Tr. Bloomfield Hills MI 48301 0002042077 N Chernett Jorey PF N X1 9778718.00 0.00 9778718.00 0.00 9778718.00 N 14.12 IN Common Stock, $0.01 par value Neuronetics, Inc. 3222 PHOENIXVILLE PIKE MALVERN PA 19355 This Amendment No. 1 to Schedule 13D ("Amendment No. 1") amends and supplements the Schedule 13D initially filed by the Reporting Person on March 31, 2026 (the "Original Schedule 13D") with respect to the Shares. Except as specifically amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Original Schedule 13D. Item 4 is hereby amended to add the following: On April 6, 2026, the Reporting Person delivered a letter (the "Letter") to the Board of Directors of the Issuer (the "Board") calling for the immediate initiation of a comprehensive review of strategic alternatives, including the potential sale of the Issuer's transcranial magnetic stimulation ("TMS") business. In the Letter, the Reporting Person expressed the view that the Issuer's current structure and strategy are not maximizing shareholder value and that separating or divesting the TMS business should be evaluated as part of a broader strategic review. The Reporting Person also noted that such a transaction could enhance the Issuer's financial flexibility and allow for a more focused strategic direction. The Reporting Person urged the Board to engage qualified investment bankers and immediately commence a formal process to evaluate strategic alternatives. A copy of the Letter is filed as Exhibit 1 to this Amendment No. 1 and is incorporated herein by reference. Item 7 is hereby amended to add the following: Exhibit 1: Letter from Jorey Chernett to the Board of Directors of Neuronetics, Inc., dated April 6, 2026. Chernett Jorey /s/ Jorey Chernett Jorey Chernett 04/08/2026